抗不安薬活用マニュアル

出版社： 先端医学社
著者：
発行日： 2006-02-01
分野： 臨床医学：内科  >  精神医学
ISBN： 4884072359
電子書籍版： 2006-02-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,750 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,375 円(税込)

購入する

商品紹介

抗不安薬の有用性の見直しと、他剤との併用など、抗不安薬を活用する際に必要な情報を網羅。
近年、社会不安障害などの不安障害が注目されている。本書では薬剤を適正に使用するために必要な各々の特長や有害事象、注意点などを詳述している。一方、治療の導入に重要な診断についても解説し、処方例や質問表などを具体的にあげており、実際の臨床に役立つマニュアルとなっている。

目次

  • 抗不安薬活用マニュアル

    ―目次―

    【総論】
    　１．不安障害の病態と診断をみる
    　　　　―不安障害はどのような病気か―
    　２．抗不安薬の薬理をみる

    【PART1　現状】
    　１．不安障害の治療法における変遷と課題をみる
    　２．抗不安薬の処方状況をみる
    　　　　―近年わが国における処方状況を考察する―

    【PART2　展望と実践】
    　１．各不安障害の診断における要点をみる
    　２．不安障害・睡眠障害に対する使い方をみる
    　　1)不安障害の代表的疾患における治療法
    　　2)睡眠障害の治療法
    　３．うつ病・高齢者に対する使い方をみる
    　　1)うつ病と抑うつ状態における治療法
    　　2)高齢者に対する治療における注意点
    　４．薬物・アルコール依存症・統合失調症に対する使い方をみる
    　　1)薬物・アルコール依存症における抗不安薬の使用
    　　2)統合失調症における抗不安薬の使用
    　５．抗不安薬投与時の有害事象とその対応をみる
    　６．抗不安薬投与時の薬物間相互作用による有害事象をみる
    　７．抗不安薬としてのSSRIの役割と展開をみる
    　８．薬剤管理の実践と誤投与防止のポイントをみる

    【PART3　処方例からみる抗不安薬の使い方】
    　処方例１：統合失調症,49歳女性
    　処方例２：解離性障害,39歳女性
    　処方例３：特定不能の不安障害,42歳男性
    　処方例４：パニック障害（軽症）,60歳女性
    　処方例５：社会不安障害,41歳女性
    　処方例６：隔日の不眠を主訴としたうつ病,50歳代女性
    　処方例７：強い不安と一過性の妄想を伴ううつ病,60歳代女性
    　処方例８：アルコール依存症,49歳男性
    　処方例９：パニック障害,35歳女性
    　処方例１０：不眠症,55歳女性
    　処方例１１：社会不安障害,24歳女性

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【総論】

P.16 掲載の参考文献
1) 笠原嘉:不安の病理, 岩波書店, 東京, 1981
 
2) 上島国利:実地医家が知っておきたい抗不安薬の知識と使い方 (改訂3版), ライフ・サイエンス, 東京, 2000
 
3) The Brain from Top to Bottom:http://www.thebrain.mcgill.ca/flash/index_i.html
 
4) 山田茂人:不安障害の神経科学.最新精神医学 8:525-535, 2003
 
5) 野村穂一郎:全般性不安障害の概念は成立するか. 最新精神医学 8:517-524, 2003
 
6) 樋口輝彦:不安障害の解明と治療薬の役割. 毎日ライフ2002年6月号, 毎日新聞社, 東京, 2002
 
P.23 掲載の参考文献
1) 田中正敏:パニック障害の基礎と臨床, 白倉克之, 山田和夫編, 金剛出版, 東京, 2000, p.162
 
2) 上島国利, 久保木富房監修:抗不安薬と睡眠薬の使い方. アルタ出版, 東京, 2002, p.20
 
3) 田中正敏:パニック障害の基礎と臨床, 白倉克之, 山田和夫編, 金剛出版, 東京, 2000, p.151
 
4) 尾鷲登志美:各種抗不安薬の使い分け. 今月の治療 13:819-825, 2005
 
5) 中村三孝:セロトニン (5-HT)1A作動薬の薬効薬理作用. 臨床精神薬理 1:497-505, 1998
 
6) Nutt DJ, Forshall S, Bell C et al:Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9 (suppl):S81-S86, 1999
 
7) Vaswani M, Linda FK, Ramesh S:Role of selective serotonin reuptake inhibitors in psychiatric disorders:a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85-102, 2003
PubMed

【PART 1 現況】

P.35 掲載の参考文献
1) 牛島定信, 宮田久嗣:神経症概念の変遷と薬物療法. 臨床精神薬理 1:487-496, 1998
 
2) 村崎光邦:抗不安薬開発の歴史と展望. 臨床精神薬理 6:671-688, 2003
 
3) デーヴィッド・ヒーリー (林建郎, 田島治訳):抗うつ薬の時代-うつ病治療薬の光と影-, 星和書店, 東京, 2004
 
4) 中村三孝:セロトニン(5-HT)1A作動薬の薬効薬理作用. 臨床精神薬理 1:497-505, 1998
 
5) 尾鷲登志美, 大坪天平:Serotonin 系抗不安薬の臨床応用と問題点. 臨床精神薬理 6:723-729, 2003
 
6) National Disease and Therapeutic Index (NDTI). Plymouth Meeting, Pa:IMS Health; December 2001 (Stahl SM:Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 63:756-757, 2002)
 
7) 尾鷲登志美, 上島国利:主要な薬物依存症のニューロサイエンス的側面. Benzodiazepine の常用量依存症. Clinical Neuroscience 22:705-708, 2004
 
8) 尾鷲登志美, 上島国利:抗不安薬の種類. Modern Physician 24:1019-1024, 2004
 
9) 石郷岡純:新規抗不安薬の開発動向. 臨床精神薬理 6:741-749, 2003
 
10) Bandelow B, Zohar J, Hollander E et al:World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-199, 2002
 
P.46 掲載の参考文献
1) 中枢神経系用薬. 月刊ミクス 2001年増刊号, 2001, pp.53-66
 
2) 村崎光邦:わが国における向精神薬の現状と展望-21世紀を目指して-. 臨床精神薬理 4:3-27, 2001
 
3) Medical Letter 関連:医薬調査資料 (1999-2005), http://www.fukumi.co.jp/mm/add/ml_add.htm
 
4) マーケティングシェア・シリーズ第31弾 (2003年) 第11同中枢神経系用薬 (その3):マイナー・トランキライザー, メジャー・トランキライザー. 抗うつ薬. 国際医薬品情報 789:35-38, 2005
 
5) FDA APPROVED LABELING FOR XANAX XR Attachment to FDA Approval Letter for NDA 21-434, http://www.fda.gov/cder/foi/label/2003/21434_xanax_lbl.pdf
 
6) 尾鷲登志美, 大坪天平:Serotonin 系抗不安薬の臨床応用と問題点. 臨床精神薬理 6:723-729, 2003
 
7) Hidalgo RB, Barnett SD, Davidson JR:Social anxiety disorder in review:two decades of progress. Int J Neuropsychopharmacol 4:279-298, 2001
PubMed
8) 太田晴久, 林正年, 尾鷲登志美:昭和大学病院附属東病院精神科外来における初診時の処方調査～大うつ病性障害を中心として～. トレドミン研究会, 東京, 2005
 
9) 尾鷲登志美:各種抗不安薬の使い分け. 今月の治療 13:824, 2005
 

【PART 2 展望と実践】

P.59 掲載の参考文献
1) 高橋三郎, 大野裕, 染矢俊幸訳:DSM-IV-TR 精神疾患の診断・統計マニュアル, 医学書院, 東京, 2002
 
2) 井上令一, 四宮滋子監訳:カプラン臨床精神医学テキスト, メディカル・サイエンス・インターナショナル, 東京, 2004
 
P.73 掲載の参考文献
1) 鈴木映二, 八木剛平監訳:不安障害の治療. 精神科治療薬の処方ガイドライン(モーズレイ 2001 年版), 星和書店, 東京, 2001, pp.85-90
 
2) 勝久寿, 中山和彦:抗不安薬の選び方と使い方. メンタルケアドラッグ&治療ガイド-病態, 症状, 行動からみた処方ガイド-, 上島国利編, メディカルドゥ, 大阪, 2003, pp.29-36
 
3) 山下さおり, 大嶋明彦, 工藤行夫:抗不安薬概論. 別冊日本臨牀 領域別症候群シリーズ No.38 精神医学症候群 (I), 日本臨床社, 東京, 2003, pp.604-607
 
4) 尾鷲登志美:各種抗不安薬の使い分け. 今月の治療 13:819-825, 2005
 
5) 融道男:向精神薬マニュアル, 医学書院, 東京, 2001
 
6) 篠田直之, 児玉和宏, 坂本忠ほか:恐慌性障害に対する抗不安薬 ethyl loflazepate の有用性について. 臨床精神薬理 3:1409-1419, 2000
 
7) Noyes R Jr, Garvey MJ, Cook B et al:Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 148:517-523, 1991
PubMed
8) 福原秀浩, 梅影正, 山中学ほか:不安障害とうつ病に対する BZD + SSRI 併用療法, 新薬と臨床 52:1117-1123, 2003
Medical*Online
9) Nelson J, Chouinard G:Guidelines for the clinical use of benzodiazepines:pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 6:69-83, 1999
PubMed
10) Furukawa TA, Streiner DL, Young LT:Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord 65:173-177, 2001
PubMed
11) Goddard AW, Brouette T, Almai A et al:Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58:681-686, 2001
PubMed
12) Hallfors DD, Saxe L:The dependence potential of short half-life benzodiazepines:a meta-analysis. Am J Public Health 83:1300-1304, 1993
PubMed
13) 久保千春, 千田要一:皮膚科医, 内科医も安心して使える, 抗不安薬, 睡眠薬, 抗うつ薬. 皮膚心療内科, 宮地良樹, 久保千春編, 診断と治療社, 東京, 2004
 
14) 千田要一, 久保千春:心療内科の治療法. 現代心療内科学, 久保千春, 中井吉英, 野添新一編, 永井書店, 東京, 2003
 
15) 千田要一, 久保千春:SSRI. 内科 92:654-658, 2003
 
16) 森田順, 鈴木尚:抗不安薬メイラヅクス・ (ロフラゼプ酸エチル) の代謝に関与するヒト肝チトクロム P450 (CYP) 分子種の同定. 分子精神医学 4:103-108, 2004
 
17) 久保千春編:各診療科での抗不安薬治療の実際-症例呈示-. 一般心療科医のための抗不安薬の選び方と使い方. モダンフィジシャン 24:1051-1094, 2004
 
18) 千田要一, 久保千春:心因反応が強い症例. 喘息 18:37-41, 2005
Medical*Online
P.88 掲載の参考文献
1) 財団法人健康・体力づくり事業財団:健康づくりに関する意識調査報告書, 1997
 
2) 内村直尚, 松山誠一郎:睡眠薬服用の現状とその対応. こころの臨床 a・la・carte 22:345-350, 2003
 
3) 村崎光邦:展望-睡眠薬の歴史的展開-. こころの臨床 a・la・carte 22:321-333, 2003
 
4) 田ヶ谷浩邦, 内山真:睡眠薬の種類とその使用法. こころの臨床 a・la・ carte 22:334-344, 2003
 
5) Kusunoki K, Kitajima T, Ozaki N:Does quazepam influence sleep and daytime activity in healthy adults? Sleep Biol Rhythms 1:171-172, 2003
 
6) 竹内尚子:睡眠薬の紹介. 臨床精神薬理 4 (増刊):S73-S90, 2001
 
7) Dement WC:Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test. J Clin Psychiatry (suppl) 52:S31-S37, 1991
 
8) Nofzinger EA, Buysse DJ, Germain A et al:Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 161:2126-2128, 2004
PubMed
9) 内山真, 石束嘉和, 伊藤洋ほか:睡眠障害の対応と治療ガイドライン. じほう, 東京, 2002
 
10) American Sleep Disorders Association:International classification of sleep disorders, revised:Diagnostic and coding manual, Rochester, Minnesota, 1997
 
11) Weitzman ED, Czeisler CA, Coleman RM et al:Delayed sleep phase syndrome. A chronobiological disorder with sleep-onset insomnia. Arch Gen Psychiatry 38:737-746, 1981
PubMed
12) Ozaki N, Iwata T, Itoh A et al:A treatment trial of delayed sleep phase syndrome with triazolam. Jpn J Psychiatry Neurol 43:51-55, 1989
PubMed
P.99 掲載の参考文献
1) Stahl SM:Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 63:756-757, 2002
 
2) Stahl SM:Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry 63:854-855, 2002
PubMed
3) 田島治:不安を伴ううつ病と不安障害に対するベンゾジアゼピン (BZD) とSSRI の併用療法-その臨床的意義と基礎的メカニズムの再検討-. 分子精神医学 3:130-139, 2003
 
4) 田中和秀, 尚橋淳, 森信繁ほか:抗うつ薬の抗不安作用の本態と臨床. 臨床精神薬理 6:731-739, 2003
 
5) 早川達郎, 中島常男, 亀井雄一:Benzodiazepine 系抗不安薬の臨床応用と問題点. 臨床精神薬理 6:705-711, 2003
 
6) Food and Drug Administration Center for Drug Evaluation and Research:Summary minutes of the psychopharmacologic drugs advisory committee meeting and the pediatric subcommittee of the anti-infective drugs advisory committee. Februay 2, 2004 (http://www.fda.gov/)
 
7) Medicines and healthcare products regulatory agency:Selective serotonin reuptake inhibitor (SSRI) antidepressants-finding of the committee on safety of medicines (CMS) working group. December 6, 2004 (http://www.mhra.gov.uk/)
 
8) Rickels K, Chung HR, Csanalosi IB et al:Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 44:862-866, 1987
PubMed
9) Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S et al:Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Psychopharmacology 120:109-115, 1995
PubMed
10) 高塩理, 大坪天平:思いやりのある抗不安薬治療. 臨床精神薬理 8:671-677, 2005
 
11) 伊藤雅臣:ベンゾジアゼピン系薬の臨床薬理. 分子精神医学 4:182-186, 2004
 
12) Furukawa T, Streiner DL, Young LT et al:Antidepressant plus benzodiazepine for major depression. The Cochrane Library 4:1-21, 2000
 
13) Smith WT, Londborg PD, Glaudin V et al:Short-term augmentation of fluoxetine with clonazepam in the treatment of depression:a double-blind study. Am J Psychiatry 155:1339-1345, 1998
PubMed
14) The royal college of psychiatrists:CR59. Benzodiazepines:risks, benefits and dependence-A re-evalution-. Council report CR59 January 1997. Royal college of psychiatrists, London, 1997
 
15) 辻敬一郎, 田島治:プライマリケアにおける抗うつ薬と抗不安薬の使い方. クリニカルプラクティス 24:49-52, 2005
 
16) 山田久美子, 穐吉條太郎:不安障害と抑うつ. 臨床精神薬理 6:1435-1443, 2003
 
17) 田島治:抗不安薬併用の問題. Modern Physician 24:1027-1030, 2004
 
18) Nutt DJ, Malizia AL:Structual and functional brain changes in posttraumatic stress disorder. Clin Psychiatry 65:11-17, 2004
 
19) 辻敬一郎, 田島治:全般性不安障害の薬理学. 精神科 5:434-438, 2004
 
20) Lydiard RB, Laraia MT, Ballenger JC et al:Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 144:664-665, 1987
PubMed
21) Shammas E:Controlled comparison of bromazepam, amitriptyline, and placebo in anxiety-depressive neurosis. Dis Nerv Syst 38:201-207, 1977
PubMed
22) Beauclair L, Fontaine R, Annable L et al:Clonazepam in the treatment of panic disorder:a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 14:111-118, 1994
PubMed
23) Cohen LS, Rosenbaum JF:Clonazepam:new uses and potential problems. J Clin Psychiatry 48 (suppl):S50-S56, 1987
 
24) Rickels K, Pereira-Ogan JA, Chung HR et al:Bromazepam and phenobarbital in anxiety:a controlled study. Curr Ther Res Clin Exp 15:679-690, 1973
PubMed
25) Fontaine R, Mercier P, Beaudry P et al:Bromazepam and lorazepam in generalized anxiety:a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 74:451-458, 1986
PubMed
26) Nelson J, Chouinard G:Guidelines for the clinical use of benzodiazepines:pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 6:69-83, 1999
PubMed
P.111 掲載の参考文献
1) Hollister L:General principles of treating the elderly with drugs. In:Clinical Pharmacology and the Aged Patients, ed. by Jarvic L, Raven Press, New York, 1981, pp.1-9
 
2) Watkins PB:Drug metabolism by cytochromes P450 in the liver and small bowel. Gastrointest Clin North Am 21:511-526, 1992
 
3) Roberts J, Tumer N:Age and diet effects on drug action. Pharmacol Ther 37:111-149, 1988
PubMed
4) Shimada T, Yamazaki H, Mimura M et al:Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals:studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423, 1994
PubMed
5) Mark TK, Peter C:Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet 33:302-312, 1997
 
6) 宍倉久里江, 上島国利:不安障害の薬物療法. 臨床精神薬理ハンドブック, 樋口輝彦, 小山司, 神庭重信編, 医学書院, 東京, 2003, pp.186-199
 
7) Woods JH, Katz JL, Winger G:Abuse liability of benzodiazepines. Pharmacol Rev 39:251-413, 1987
PubMed
8) 三浦貞則:向精神薬の適用と問題点-抗不安薬-. 精神医学 22:151-159, 1980
 
9) 村崎光邦:抗不安薬, 精神治療薬体系-抗不安薬, 睡眠薬, 星和書店, 東京, 1997, pp.1-262
 
10) Cook PJ:Benzodiazepine hypnotics in the elderly. Acta Psychiatry Scand Suppl 74:149-158, 1986
 
11) Ray WA, Griflin MR, Downey W:Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 262:3303-3307, 1989
 
P.117 掲載の参考文献
1) American Psychiatric Association Task Force on Benzodiazepine dependency:Benzodiazepine Dependence, Toxicity and Abuse:A Task Force Report of the American Psychiatric Association, American Psychiatric Association, Washington, DC, 1990
 
2) Mhatre MC, Ticku MK:Alcohol:effects on GABAA receptor function and gene expression. Alcohol Alcohol 28 (suppl):S331-S335, 1993
 
3) Lejoyeux M, Solomon J, Ades J:Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 33:563-575, 1998
PubMed
4) Shaw GK:Detoxification:the use of benzodiazepines. Alcohol Alcohol 30:765-770, 1995
PubMed
5) Mayo-Smith MS:Pharmacological management of alcohol withdrawal:a meta analysis and evidence-based practical guideline.J Am Med Assoc 278:144-151,1997
 
6) Pycha R, Miller C, Barnas C et al:Intravenous flunitrazepam in the treatment of alcohol withdrawal delirium. Alcohol Clin Exp Res 17:753-757, 1993
PubMed
7) Kranzler HR, Burleson JA, Del Boca FK et al:Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 51:720-731, 1994
PubMed
8) Rickels K, Schweizer E, Case WG et al:Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 47:899-907, 1990. Erratum in:Arch Gen Psychiatry 48:51, 1991
 
9) Schweizer E, Rickels K, Case WG et al:Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 47:908-915, 1990
PubMed
P.122 掲載の参考文献
1) Regier DA, Farmer ME, Rae DS et al:Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511-2518, 1990
PubMed
2) Carpenter WT Jr, Buchanan RW, Kirkpatrick B et al:Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry:156:299-303, 1999
PubMed
3) American Psychiatric Association:Practice Guidelines for the Treatment of Schizophrenia, American Psychiatric Press, Washington DC, 1997
 
4) Wolkowitz OM, Pickar D:Benzodiazepines in the treatment of schizophrenia:a review and reappraisal. Am J Psychiatry 148:714-726, 1991
PubMed
5) Lerner Y, Lwow E, Levitin A et al:Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 36:1061-1065, 1979
 
6) Karson CN, Weinberger DR, Bigelow L et al:Clonazepam treatment of chronic schizophrenia:negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 139:1627-1628, 1982
 
7) Stimmel GL:Benzodiazepines in schizophrenia. Pharmacotherapy 16:148S-151S, 1996
PubMed
8) van Harten PN, Kahn RS:Tardive dystonia. Schizophr Bull 25:741-748, 1999
PubMed
P.131 掲載の参考文献
1) American Psychiatric Association:Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 155 (suppl):S1-S34, 1998
 
2) Taylor D, Paton C, Kerwin R et al:The Maudsley 2003 Prescribing Guidelines (7th ed), Martin Dunitz, London, 2003
 
3) Tamblyn R, Abrahamowicz M, du Berger R et al:A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 53:233-241, 2005
PubMed
4) Cumming RG, Le Couteur DG:Benzodiazepines and risk of hip fractures in older people:a review of the evidence. CNS drugs 17:825-837, 2003
PubMed
5) Stewart SA:The effects of benzodiazepines on cognition. J Clin Psychiatry 66 (suppl):S9-S13, 2005
 
6) 樋口輝彦, 小山司, 神庭重信編:臨床神経薬理ハンドブック, 医学書院, 東京, 2003
 
7) 越野好文:向精神薬の常用量依存, メチルフェニデートと BZ. 臨床精神医学 32:549-555, 2003
 
8) Malcom R, Brady KT, Johnson AL et al:Types on benzodiazepines abuse chemically dependent inpatients. J Psychoactive Drugs 25:315-319, 1993
 
9) Rickels K, Case WG, Downing RW et al:Long-term diazepam therapy and clinical outcome. JAMA 250:767-771, 1983
PubMed
10) Sussman N:Treating anxiety while minimizing abuse and dependence. J Clin Psychiatry 54 (suppl):S44-S51, 1993
 
11) Rickels K, Case WG, Schweizer EE et al:Low-dose dependence in chronic benzodiazepine users:a preliminary report on 119 patients. Psychopharmacol Bull 22:407-415, 1986
PubMed
12) Chouinard G:Rebound anxiety:incidence and relationship to subjective cognitive impairment. J Clin Psychiatry Monograph 4:12-16, 1986
 
13) Chouinard G:lssues in the clinical use of benzodiazepines:potency, withdrawal, and rebound. J Clin Psychiatry 65 (suppl):S7-S12, 2004
 
14) Albeck JH:Withdrawal and detoxification from benzodiazepine dependence:a potential role for clonazepam. J Clin Psychiatry 48 (suppl):S43-S49, 1987
 
15) 村崎光邦:わが国における向精神. 薬の現状と展望-21世紀を目指して-. 臨床精神薬理 4:3-27, 2001
 
16) 田中輝明, 小山司:選択的セロトニン再取り込み阻害薬 SSRI. 綜合臨床 49:3049-3055, 2000
 
17) Food and Drug Administration Center for Drug Evaluation and Research:Summary minutes of the psychophamacologic drugs advisory committee meeting and the pediatric subcommittee of the anti-infective drugs advisory committee, February 4, 2004 (http://www.fda.gov/ohrms/dockets/ac/04/minutes/4006M1_Final.htm)
 
18) Culpepper L, Davidson JR, Dietrich AJ et al:Suicidality as a possible side effect of antidepressant treatment. Prim Care Companion Clin Psychiatry 6:79-86, 2004
PubMed
19) Goddard AW, Brouette T, Almai A et al:Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58:681-686, 2001
PubMed
20) Lejoyeux M, Ades J, Mourad I:Antidepressant withdrawal syndrome:recognition, prevention and management. CNS Drugs 5:278-292;1996
 
21) Price JS, Waller PC, Wood SM:A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 42:757-763, 1996
PubMed
22) Coupland NJ, Bell CJ, Potokar JP et al:Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 26:356-362, 1996
 
23) Montejo AL, Llorca G, Izquierdo JA et al:Incidence of sexual dysfunction associated with antidepressant agents:a prospective multicentre study of 1022 outpatients. J Clin Psychiatry 62 (suppl):S10-S20, 2001
 
24) Goldstein BJ, Goodnick PJ:SSRIs in affective disorder-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12 (suppl B):S55-S88, 1998
 
25) Isbister GK, Bowe SJ, Dawson A et al:Relative toxicity of serotonin reuptake inhibitors in overdose. J Toxicol Clin Toxical 42:277-285, 2004
 
26) Radomski JW, Dursun SM, Reveley MA et al:Toxic serotonin syndrome:an update and revised diagnostic criteria. J Psychopharmacol 9 (suppl):A21, 1995
 
27) Boyer EW Shannon M:The Serotonin Syndrome. N Eng J Med 352:1112-1120, 2005
 
28) 村崎光邦:Tandspirone の基礎と臨床. 臨床精神薬理 1:81-92, 1998
 
P.144 掲載の参考文献
1) Den Boer JA, Van Vliet IM, Westenberg HG:Recent advances in the psychopharmacology of social phobia. Prog Neuropsychopharmacol Biol Psychiatry 18:625-645, 1994
PubMed
2) Mancini C, Ameringen MV:Paroxetine in social phobia. J Clin Psychiatry 57:519-522, 1996
PubMed
3) Schneier FR, Saoud JB, Campeas R et al:Buspirone in social phobia. J Clin Psychopharmacol 13:251-256, 1993
PubMed
4) Ingelman-Sundberg M, Oscarson M, McLellan RA et al:Polymorphic human cytochrome P450 enzymes:an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349, 1999
PubMed
5) 神庭重信, 山田和男, 八木剛平ほか監訳:カプラン精神科薬物ハンドブック-エビデンスに基づく向精神薬療法, メディカル・サイエンス・インターナショナル, 東京, 2003
 
6) Von Moltke LL, Tran TH, Cotreau MM et al:Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region. J Clin Pharmacol 40:200-204, 2000
 
7) Suzuki Y, Shioiri T, Muratake T et al:Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients:interaction with CYP2C19 mutated alleles. Eur J Clin Pharmacol 58:829-833, 2003
 
8) Sproule BA, Naranjo CA, Brenmer KE et al:Selective seronin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinetics 33:454-471, 1997
 
9) Nolting A, Abramowitz W:Lack of interaction between citalopram and the CYP3A4 substrate triazolam. Pharmacotherapy 20:750-755, 2000
PubMed
10) Bloomer JC, Woods FR, Haddock RE et al:The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33:521-523, 1992
 
11) Sindrup SH, Brosen K, Gram LF et al:The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278-287, 1996
 
12) Von Moltke LL, Greenblatt DJ, Court MH et al:Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine:comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131, 1995
PubMed
13) Alderman J, Allison J, Chung M et al:Desipramine with paroxetine or sertraline. New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association, May 26, 1994, Philadelphia, Pa. Abstract NR610:215
 
14) Greenblatt DJ, von Moltke LL, Harmatz JS et al:Drug interactions with newer antidepressants:role of human cytochromes P450. J Clin Psychiatry 59 (suppl):S19-S27, 1998
 
15) Spigset O, Carleborg L, Hedenmalm K et al:Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 58:399-403, 1995
PubMed
16) Callillo JA, Dahl ML, Svensson JO et al:Disposition of fluvoxamine in humans is determined by the polymorphic CYP 2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60:183-190, 1996
 
17) Jeppesen U, Rasmussen BB, Brosen K et al:Fluvoxmine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 62:279-286, 1997
PubMed
18) Perucca E, Gatti G, Cipolla G et al:Inhibition of diazepam metabolism by fluvoxamine:a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56:471-476, 1994
PubMed
19) Spina E, Pollicino AM, Avenoso A et al:Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243-246, 1993
PubMed
20) Von Moltke LL, Greenblatt DJ, Duan SX et al:Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology 132:402-407, 1997
PubMed
21) Shader RI, von Moltke LL, Schmider J et al:The Clinician and drug interactions:an update. J Clin Psychopharmacol 16:197-201, 1996
PubMed
22) Prescorn SH, Alderman J, Chung M et al:Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90-98, 1994
 
23) Schmider J, Greenblatt DJ, von Moltke LL et al:Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro:studies of phenitoin parahydroxylation. Br J Clin Pharmacol 44:495-498, 1997
 
24) Shader RI, Greenblatt DJ, von Moltke LL et al:Fluoxetine inhibition of phenitoin metabolism. J Clin Psychopharmacol 14:375-376, 1994
 
25) Rapeport WG, Muirhead DC, Williams SA et al:Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 57 (suppl):S24-S28, 1996
 
26) Hamelin BA, Turgeon J, Vallee F et al:The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 60:512-521, 1996
 
27) Kultz DL, Bergstrom RE Goldberg MJ et al:The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 62:145-156, 1997
 
28) Spina E, Avenoso A, Campo GM et al:Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol 43:315-318, 1997
PubMed
29) Furlanut M, Benetello P, Spina E:Pharmacokinetic optimisation of tricyclic antidepressant therapy. Clin Pharmacokinet 24:301-318, 1993
PubMed
30) Gram LF, Guentert TW, Grange S et al:Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2:a panel study. Clin Pharmacol Ther 57:670-677, 1995
 
31) Zimmer R, Gieschke R, Fischbach R et al:Interaction studies with moclobemide. Acta Psychiatr Scand Suppl 360:84-86, 1990
PubMed
32) Cho JY, Yu KS, Jang IJ et al:Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacology 53:393-397, 2002
 
33) Gram LF, Brosen K:Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group. Br J Clin Pharmacology 35:649-652, 1993
 
34) Jedrychowski M, Feifel N, Bieck PR et al:Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine. J Pharm Biomed Anal 11:251-255, 1993
PubMed
35) Waldmeier PC:Pharmacology and pharmacokinetics of brofaromine and moclobemide in animals and humans. In:Clinical Advances in Monoamine Oxidase Inhibitor Therapies, ed. by Sidney H, Kennedy MD, American Psychiatric Press, Washington DC, 1994, pp.33-59
 
36) Harvey AT, Preskorn SH:Cytochrome P450 enzymes:interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 16:273-285, 1996
 
37) Harvey AT, Preskorn SH:Cytochrome P450 enzymes:interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 16:345-354, 1996
 
38) Dingemanse J:An update of recent moclobemide interaction data. Int Clin Psychopharmacol 7:167-180, 1993
PubMed
39) van Vliet IM, den Boer JA, Westenberg HG et al:Clinical effects of buspirone in social phobia:a double-blind placebo-controlled study. J Clin Psychiatry 58:164-168, 1997
PubMed
40) Van Ameringen M, Mancini C, Wilson C et al:Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 39:115-121, 1996
PubMed
41) Daniel W:Metabolism of psychotropic drugs:pharmacological and clinical relevance. Pol J Pharmacol 47:367-379, 1995
PubMed
42) Chouinard G, Lefko-Singh K, Teboul E:Metabolism of anxiolytics and hypnotics:benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 19:533-552, 1999
 
43) Clay PG, Adams MM:Pseudo-Parkinson disease secondary to ritonavirbuspirone interaction. Ann Pharmacother 37:202-205, 2003
PubMed
44) Johnson JA:CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 294:1099-1105, 2000
PubMed
45) Lu P, Schrag ML, Slaughter DE:Mechanism-based inhibition of human liver microsomal cytochrome P4501A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 31:1352-1360, 2003
 
46) Mayersohn M, Guentert TW:Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 29:292-332, 1995
PubMed
47) Luchowska E, Luchowski P, Wielosz M et al:Propranolol and metoprolol enhance the anticonvulsant action of valproate and diazepam against maximal electroshock. Pharmacol Biochem Behav 71:223-231, 2002
PubMed
P.153 掲載の参考文献
1) 井上猛, 小山司:不安・恐怖のセロトニン仮説. 脳と精の医 11:341-351, 2000
 
2) 田島治:不安障害の薬物療法の最近の動向. 日本神経精神薬理学雑誌 24:133-136, 2004
 
3) Stahl SM:Don't ask, don't tell, but benzodiazepines are still the leading treatment for anxiety disorder. J Clin Psychiatry 63:756-757, 2002
 
4) Stahl SM:Independent actions on fear circuits may lead to therapeutic synergy for anxiety disorder when combining serotonergic and GABAergic agents. J Clin Psychiatry 63:854-855, 2002
PubMed
5) Wittchen HU, Zhao S, Kessler RC et al:DSM-III-R generalized anxiety disorder in the national cormorbidity survey. Arch Gen Psychiatry 51:355-364, 1994
 
6) Stein DJ:Clinical Manual of Anxiety Disorders, ed. by Stein DJ, American Psychiatric Publishing, Arlington, 2004, pp.1-12
 
7) Figgitt DP, MaClellan KJ:Fluvoxamine. An up dated review of its use in the management of adults with anxiety disorders. Drugs 60:925-954, 2000
 
8) Wagstaff AJ, Cheer SM, Matheson AJ et al:Paroxetine:an update of its use in psychiatric disorders in adults. Drugs 62:655-703, 2002
PubMed
9) Hollander E, Simeon D:Somatic treatments. Concise Guide to Anxiety Disorders, ed. by Hollander E, American Psychiatric Publishing, Washington, DC, 2005, pp.147-202
 
10) 田島治:不安障害の薬物療法. 日本精神神経学雑誌 106:1283-1288, 2004
 
P.165 掲載の参考文献
1) 関口久紀:医療機関における向精神薬の管理に関する問題点. 日本病院薬剤師会雑誌 35:423-431, 1999
 
1) 東京都福祉保健局健康安全室薬務課:向精神薬取扱いのてびき (平成16年10月改訂), 2004
 
2) 竹内尚子:向精神薬の管理・取扱い, 日本病院薬剤師会雑誌 35:1529-1531, 1999
 
3) 渡部恵, 杉浦宗敏, 清野敏一ほか:処方オーダリングシステムにおける入力ミスの防止法とその評価 3文字入力及び警告画面表示システムの有用性. 薬学雑誌 122:841-847, 2002
 

書評

最近チェックした商品履歴

Loading...